N. Engl. J. Med. 2012-04-19
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Abstract
Background
Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder cancer. In other disease sites, synchronous chemoradiotherapy has been associated with increased local control and improved survival, as compared with radiotherapy alone.
Methods
In this multicenter, phase 3 trial, we randomly assigned 360 patients with muscle-invasive bladder cancer to undergo radiotherapy with or without synchronous chemotherapy. The regimen consisted of fluorouracil (500 mg per square meter of body-surface area per day) during fractions 1 to 5 and 16 to 20 of radiotherapy and mitomycin C (12 mg per square meter) on day 1. Patients were also randomly assigned to undergo either whole-bladder radiotherapy or modified-volume radiotherapy (in which the volume of bladder receiving full-dose radiotherapy was reduced) in a partial 2-by-2 factorial design (results not reported here). The primary end point was survival free of locoregional disease. Secondary end points included overall survival and toxic effects.
Results
At 2 years, rates of locoregional disease-free survival were 67% (95% confidence interval [CI], 59 to 74) in the chemoradiotherapy group and 54% (95% CI, 46 to 62) in the radiotherapy group. With a median follow-up of 69.9 months, the hazard ratio in the chemoradiotherapy group was 0.68 (95% CI, 0.48 to 0.96; P=0.03). Five-year rates of overall survival were 48% (95% CI, 40 to 55) in the chemoradiotherapy group and 35% (95% CI, 28 to 43) in the radiotherapy group (hazard ratio, 0.82; 95% CI, 0.63 to 1.09; P=0.16). Grade 3 or 4 adverse events were slightly more common in the chemoradiotherapy group than in the radiotherapy group during treatment (36.0% vs. 27.5%, P=0.07) but not during follow-up (8.3% vs. 15.7%, P=0.07).
Conclusions
Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with radiotherapy alone, with no significant increase in adverse events. (Funded by Cancer Research U.K.; BC2001 Current Controlled Trials number, ISRCTN68324339.).
Related Questions
How do you approach elective nodal irradiation in muscle-invasive bladder cancer?
The evidence regarding elective nodal irradiation (ENI) in patients undergoing organ preservation with chemotherapy and radiation is mixed, especially when considering data from surgical studies. A meta-analysis involving approximately 17,000 patients indicated that nodal dissection improved outcome...
Do you include the prostate when treating bladder cancer?
Dr. @Dr. First Last is correct, in the North American trials prostate has been included in the lower dose CTV on grounds that urethral and prostatic stroma can both be involved and to recapitulate surgical treatment where the prostate would be removed with the cystoprostatectomy. A study in PRO last...
In patients who have residual bladder tumors after maximal TURBT, would you boost the GTV above typical doses, 55 Gy/20 fractions or 64 Gy/32 fractions, assuming you can meet constraint?
In the British study, (55/20 + MMC), these patients were encouraged but not required to undergo complete TURBT; ~45% in each arm of the study did not get a complete TURBT. No boost was given to those who did not get a complete TURBT. As this is the only RCT (for some reason, the RTOG never did an RT...
Which cisplatin regimen is preferred for concurrent chemoradiation for definitive treatment of muscle invasive bladder cancer?
There is not a single optimal chemotherapy regimen that has been determined based on a large randomized trial evaluating chemoradiation for muscle-invasive bladder cancer. Indeed, the only chemotherapy regimen proven to improve locoregional outcomes (but not survival) in a phase III trial is 5FU + M...
What chemotherapy do you use with radiation for urothelial carcinoma with squamous differentiation?
In case of primary or dominant urothelial carcinoma with squamous cell features, would approach similar to pure urothelial carcinoma and consider same radio-sensitizing chemo that we are using in S1806 phase III trial. Doses below may not fully reflect S1806 protocol and also depends on the patient ...
How do you dose concurrent chemotherapy with once daily radiation for bladder preservation in urothelial carcinoma?
Two contemporary trials which used daily radiotherapy and concurrent chemotherapy are BC2001 and RTOG 0712 with concurrent chemotherapy schedules as below. Other regimens such as platinum alone have been reported on as well.BC2001: 5FU: 500mg/m²/d d1-5 & d16-20 MMC: 12mg/m² d1 Rationale: The study...
What bowel constraints do you use when treating definitive bladder?
I often find a V60<10 cc bowel constraint too restrictive and challenging to meet without significant compromise of tumor coverage due to the aforementioned tendency of the bowel to sit atop the bladder dome, and requisite standard PTV margins.First and foremost, I obtain daily CBCT for these patien...
For non-metastatic MIBC patients with incomplete debulking TURBT, who are not surgical candidates for cystectomy or repeat TURBT, would you try chemoRT or proceed directly to systemic treatment?
Definitely chemoRT. I believe around 1/3 of patients on BC2001 had biopsy only or incomplete TURBT. No doubt maximal TURBT is preferred, but when it is not possible, that is not a contraindication to definitive treatment. If not a chemo candidate (though there are several options), I would recommend...
When treating bladder cancer with 55 Gy in 20 fractions, what small bowel dose constraints do people use?
Yes, it is hard to tell what happened on that trial because we don't know how often small bowel might have been excluded from the PTV. It would be nice to hear from others, like @Dr. First Last. And maybe theMednet can get Dr. James to join? For what it is worth, when this is an issue, I treat with...
What is a reasonable dose to treat the entire bladder for an muscle invasive, multi-focal bladder cancer in a non-surgical patient?
A variety of dosing schemes have been used in bladder-sparing trimodality (TMT) experiences from the US (RTOG/NRG trials) and the UK (BC2001 and BCON trials). In BC2001, one of the randomizations in the 2 x 2 design was to treatment of the entire bladder to the prescription dose (64 Gy in 32 fractio...
How do you determine your treatment volumes when treating with chemoradiation for bladder cancer?
Good question! The fields for bladder preservation with chemoradiation have not been standardized, and there are multiple reasonable options based on trials/experiences for certain fields. In general, it is important to try to minimize dose of RT to adjacent tissues that are more sensitive. Because ...
Under what circumstances would you recommend hypofractionated radiation for bladder cancer?
In the BC2001 study (James N, NEJM 366:1477, 2012) that showed a benefit to chemoradiotherapy over radiotherapy alone, two fractionation schemes were allowed: 64 Gy in 32 fractions of 2 Gy or 55 Gy in 20 fractions of 2.75 Gy. Of the 360 patients in the trial, 40% had the shorter, 4 week fractionatio...
How do you approach a patient with inoperable urothelial carcinoma of the bladder with persistent non-muscle invasive disease despite intravesical BCG/IFN and intravesical chemotherapy?
T1 high grade urothelial carcinoma, with persistent disease after intra-vesicular therapy (e.g., BCG) is an aggressive disease and progression to invasive urothelial cancer is common. This entity tends to be multifocal / diffuse and transurethral resection (TURBT) alone is often inadequate as defini...
When treating with chemo/RT for bladder cancer, how concerned are you with small bowel dose constraints when boosting the bladder to 60 Gy?
This is an excellent question, and something we struggle with. DVH parameters are important considerations, but I also feel that sometimes we put too much emphasis on dose contraints; as if the sky will fall if you pass a threshold. Exceeding a parameter is no guarantee of good or bad outcome, but m...
When treating bladder cancer with CRT in the bladder preservation paradigm, do you cone down to partial bladder or the whole bladder?
I agree with @Dr. First Last about whole vs. partial bladder "cone-down", although in my experience I'm much less like than @Dr. First Last to treat partial bladder. In addition to the trials mentioned, the old SWOG experience (Combined 5-fluorouracil and irradiation for transitional cell carcinoma ...
What RT dose (with chemo) would you use for small cell of the bladder?
Even in lung small cell cancer, we don't have consensus regarding the appropriate dose (see NCCN SCLC Principles of Radiation Therapy, for example). And of course, bladder small cell cancer is relatively uncommon so there's less data available.Thus my approach has been to use RT doses that are consi...